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Background: A prospective, single-arm, open-label, multicenter, nonrandomised phase II trial to evaluate efficacy
and safety of short fludarabine, mitoxantrone, and rituximab (FMR) induction followed by radioimmunotherapy, in
untreated, intermediate/high-risk follicular non-Hodgkin’s lymphoma (NHL) patients.
Patients and methods: Fifty-five patients were treated using a sequential treatment schedule of four induction
cycles of FMR chemoimmunotherapy, and a subsequent consolidating single administration of 90Y-ibritumomab
tiuxetan (90Y-IT), 8–14 weeks later. Patients were eligible for radioimmunotherapy if at least in partial response (PR)
after induction, with normal platelet and granulocyte counts and a bone marrow infiltration £25%. Primary study end
points were response rate and hematologic toxic effects; secondary end points were overall survival (OS) and
progression-free survival (PFS).
Results: All the 55 patients received four induction cycles with an overall response rate of 96% (38 complete
responses [CR] and 15 PR). Fifty-one patients (38 in CR and 13 in PR) received 90Y-IT. By the end of the treatment,
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49/55 patients achieved a CR. With a median follow-up of 21 months, the estimated 3-year PFS was 81% and the 3-
year OS 100%.
Conclusions: This study has established feasibility, tolerability, and efficacy of a regimen composed by short FMR
induction with 90Y-IT consolidation in untreated intermediate/high-risk follicular NHL patients.
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introduction
The first choice initial treatment of patients with indolent non-
Hodgkin’s lymphomas (NHLs) who are not eligible for clinical
trials has historically included either alkylating-based regimens—
e.g. CVP (cyclophosphamide, vincristine, and prednisolone)—or
purine analogues, such as fludarabine. Although more
aggressive regimens—e.g. CHOP (cyclophosphamide,
adriamycin, vincristine, and prednisolone)—have been used in
the initial treatment of follicular lymphoma, there is no evidence
of a superior response rate or duration of remission compared
with CVP [1]. Fludarabine-based regimens are highly effective
but not superior to CVP in terms of remission duration or overall
survival (OS) [2].
The treatment paradigm for treating advanced-stage
follicular lymphoma has changed with the use of the anti-
CD20 monoclonal antibody, rituximab (R). The first phase II
study regarding a combination of chemotherapy (CHOP) and
rituximab was presented by Czuczman et al. [3] in patients
with untreated follicular lymphoma. Phase III randomized
trials have then demonstrated a significant improvement in
outcome by combining chemotherapy regimens with
rituximab [4–6].
Radioimmunotherapy has emerged as an important
treatment option for patients with B-cell NHL. Ibritumomab
is a murine monoclonal immunoglobulin G1/ kappa antibody
directed to CD20, a surface antigen that is expressed on 90%
of B-cell lymphomas [7]; it is conjugated to the metal chelator
tiuxetan for the retention of the beta emitter 90Yttrium.
In the initial phase I-II trial of 90Yttrium-ibritumomab
tiuxetan (90Y-IT), responses were seen in 28 (82%) of the 34
patients with pretreated indolent NHL [8]. Witzig et al. [9]
compared 90Y-IT with a standard dose of rituximab in
a randomized controlled phase III study in relapsed or
refractory indolent follicular NHL, showing statistically
significant higher overall response and complete response
(CR) rates.
Following reports have confirmed the safety and efficacy of
90Y-IT in pretreated patients with follicular NHL [10, 11].
Moving from these results, further investigations have
monitored the role of radioimmunotherapy (using
131I-tositumomab or 90Y-IT) as a consolidation treatment after
a chemotherapy induction [12–14] in follicular NHL patients.
More specifically, the sequential treatment was represented by
fludarabine alone [12] or by a fludarabine-containing regimen
[13] followed by 90Y-IT; a CHOP-based chemotherapy
induction was instead used by Press et al. [14], followed by
131I-tositumomab administration. The initial reports from
these studies have demonstrated the feasibility, tolerability, and
efficacy of the combination regimens, being the induction
phase represented by chemotherapy, without the addition of
rituximab. A recent randomized trial has demonstrated
a marked improvement in progression-free survival (PFS) if
90Y-IT is administered after chemotherapy, as part of a front-
line treatment [15].
Recently, this innovative approach combining induction
chemotherapy and subsequent consolidation with 90Y-IT has
been upgraded by the shortening of chemotherapy duration
(trying to decrease the potential long-term toxic effects of
antiblastic drugs), and—at the same time—by the insertion of
rituximab in any chemotherapy regimen [16–18].
In force of these findings, and on the basis of our previously
published report on the ‘FLUMIZ’ study [13], we have decided
to investigate the efficacy and safety of the combination of
a short course (four cycles instead of six) of fludarabine,
mitoxantrone, and rituximab (FMR) followed by a single
infusion of 90Y-IT, in untreated intermediate/high-risk
follicular NHL patients.
patients and methods
patients
Patients aged ‡18 with biopsy-proven, bidimensionally measurable, stage
III or stage IV follicular grade 1–2 NHL expressing the CD20 antigen were
considered eligible for this prospective, single-arm, open-label, multicenter
(three major Italian cooperative institutions) nonrandomised phase II trial.
Patients were to be previously untreated and with clear indication to
therapy; they should have a World Health Organization (WHO)
performance status of two or less and a Follicular Lymphoma International
Prognostic Index (FLIPI, [19]) score ‡2.
All diagnostic biopsies were reviewed by an expert pathologist (SP) in
accordance with the WHO classification [20]. All patients had either
a follicular or a follicular and diffuse pattern, typically expressing the
CD10+, Bcl-6+, and Bcl-2+ phenotype. None of the specimen was IRF4+.
The Ki-67 value ranged from 5% to 20%.
All the patients underwent a full medical history; a physical examination;
complete blood cell and platelet counts; a computed tomography (CT) scan
of neck, chest, abdomen and pelvis (with and without contrast); a whole-
body 18F-fluorodeoxyglucose-positron emission tomography (PET) scan,
and a bone marrow aspiration and biopsy. Disease stage was established
according to the Ann Arbor staging system. Bulky disease was defined as the
presence of a nodal or extranodal mass ‡10 cm on its major diameter, as
documented on CT scan. Patients were also tested for serum creatinine,
liver function tests (including hepatitis-B virus antigens, and hepatitis-C
virus antibodies), uric acid, lactate dehydrogenase, human
immunodeficiency virus, and underwent urinalysis and
electrocardiography. Patients with a history of impaired cardiac status were
evaluated by echocardiography and were considered eligible if the cardiac
ejection fraction was within normal ranges.
All patients were notified of the investigational nature of this study and
signed a written informed consent approved in accordance with
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institutional guidelines, including the Declaration of Helsinki. The study
was approved by the institutional review board.
treatment plan
Standard i.v. fludarabine (25 mg/m2 on days 2–4) and mitoxantrone (10
mg/m2 on day 2) regimen, with the addition of rituximab (375 mg/m2 on
day 1) was administered on a 28 day-schedule for four cycles.
If there had been <1500/ll granulocytes or <100 000/ll platelets by the
time the next cycle was due, treatment should have been delayed for 1 week
and blood counts repeated. If blood counts had not recovered after 2 weeks,
the patient should have been treated at the 75% of the last dose received. A
subsequent dose reescalation could have been considered at the discretion
of the treating physician. Granulocyte colony-stimulating factor (G-CSF)
was not administered to prevent neutropenia, but patients with grade 3–4
neutropenia or neutropenic fever between cycles were allowed to receive
growth factors, at the physician’s discretion.
Two to 3 weeks after the completion of the fourth cycle of FMR regimen,
patients were restaged by physical examination, blood tests, CT scan, PET
scan, and bone marrow aspiration and biopsy. Patients in at least a partial
response (PR) were considered eligible for consolidation therapy with
90Y-IT, provided their granulocyte counts were greater than 1.5 · 109/l,
platelet counts exceeded 100 · 109/l, and lymphoma bone marrow
infiltration was <25% of the total cellularity. Responses were classified
according to the revised response criteria for malignant lymphomas [21].
Once the restaging procedures have been fully accomplished, eligible
patients received one course of 90Y-IT within 12 weeks. It consisted of an
initial infusion of rituximab at 250 mg/m2 on day 1 and a subsequent
infusion at the same dose on day 8 (61 day); the second infusion of
rituximab was then followed by a weight-based dose of 90Y-IT,
administered as a slow i.v. push over 10 min. The dose of 90Y-IT was
established on 11.1 MBq/kg (0.3 mCi/kg) for patients with pretreatment
platelet counts ranging from 100 · 109/l to 149 · 109/l, and on 14.8 MBq/
kg (0.4 mCi/kg) for those with counts of 150 · 109/l or higher. In any case,
the maximum total dose has never exceeded 1184 MBq (32 mCi). 90Y-IT
was routinely administered on an outpatient basis in view of its beta
decay, with a complete lack of gamma emissions.
Because of the transitory myelosuppression generally observed after the
administration of 90Y-IT, complete blood cell counts with leukocyte
differential and platelet counts were carried out in all patients on a weekly
basis, from the third week after radioimmunotherapy until the complete
hematologic recovery.
Disease status was evaluated again 3 months after radioimmunotherapy
through physical examination, bone marrow biopsy (if still positive after
induction chemotherapy), CT and PET scan; other clinically relevant
information, such as the development of febrile neutropenia, the use of
antibiotics or G-CSF or blood transfusion during cytopenia and the presence
of any extra-hematologic toxicity, were recorded. Patients’ follow-up
assessment included: blood count and physical examination every 3–4 months
for the first 2 years and then every 6 months for the following 3 years, CT scan
every 6 months for the first 2 years, followed by annual imaging studies
with CT or PET/CT up to 5 years from treatment completion.
Safety and tolerability were evaluated by monitoring incidence, severity,
and type of any adverse event, according to the WHO criteria for toxicity.
molecular monitoring of minimum residual disease
In order to evaluate the molecular response to the treatment in terms of
minimal residual disease (MRD), 35 patients enrolled in this trial, who were
assessable for Bcl-2 expression in peripheral blood and/or bone marrow
aspirate both before and after treatment, have been monitored by
qualitative PCR for the presence of Bcl2-IgH rearrangement (at the major
breakpoint region and at minor cluster region breakpoints) throughout the
study, at certain time points: molecular assessment was carried out at
diagnosis, after treatment with FMR regimen, and after the infusion of 90Y-IT.
Assessment was repeated every 6 months during follow-up. Laboratory
procedures and reactants descriptions have been reported elsewhere [13].
Molecular complete response was defined as the absence of Bcl-IgH
rearrangement in both bone marrow and peripheral blood samples, in atleast
two independent repetitions.
statistical analysis
Sample size estimation was carried out by single stage procedure [22].
Previous experience shows that the overall response rate is 50%. Defining
p0 as the proportion of responses below which treatment does not warrant
further investigation and pa as the proportion of responses beyond which
a phase III trial should be carried out, we set: p0 = 0.5 and pa = 0.8. The
number of patients needed, given an a error at 0.05 two-sided and a power
of 12b = 80%, was 55 and the number of successes (overall responses) 40.
If, by the end of the trial, at least 40 responses were observed, the treatment
regimen would be accepted for a phase III trial [22].
Primary end points were efficacy (measured by overall response rate) and
safety (measured in function of grade 3–4 hematologic toxic effects).
Secondary end points were OS and PFS.
Overall objective response rate (ORR) is defined as the proportion of patients
with complete response (CR) or PR according to revised response criteria for
malignant lymphomas [21]. PFS is defined as the time from study entry to
the first documentation of objective tumor progression or death due to any
cause. OS and PFS curves were plotted by the Kaplan–Meier method [23].
Comparisons were carried out with Pearson’s chi-squared test on
absolute frequencies and with Wilcoxon test for equality of survivor
functions.
The intention-to-treat analysis set was used for all study end points.
Demographics and patients’ characteristics were summarized by descriptive
statistics. Statistical analyses were carried out with Stata 11 (StatCorp LP,
College Station, TX) and P values were set at 0.05.
This trial is registered as a European Standard Controlled Trial on the
EudraCT website http://oss-sper-clin.agenziafarmaco.it, number 2006-
004850-26 and at http://ClinicalTrials.gov, ID NCT00859001.
results
Fifty-five patients (25 men and 30 women) were included in the
trial at three major Italian cooperative institutions between
December 2006 and November 2008, when the study reached
completion. Patients’ characteristics are listed in Table 1.
Median age was 56 years (range 26–84 years) and median time
from diagnosis to study entry was 3 months (range 1–6
months). Twenty patients had stage III disease and 35 had stage
IV, with bone marrow involvement in 30 cases. Eleven patients
presented with bulky disease.
At the time of the first reassessment, i.e. after the four cycles
of the FMR induction regimen (Figure 1), the overall response
rate was 96%, with 38 out of 55 patients achieving a CR and 15
a PR; the remaining two patients showed progressive disease,
being therefore ineligible for further treatment.
Fifty-one patients were deemed eligible for consolidation
with 90Y-IT: more specifically, all the patients with metabolic
CR and 13 patients with PR (all the PR patients were PET
positive). The remaining two patients, both in PR, were
excluded from the second part of the treatment program
because of a bone marrow infiltration greater than the 25% of
cellularity, as documented by a bone marrow biopsy carried out
upon this time. There was no evidence of any patient receiving
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a reduced dose of 90Y-IT because of persisting
thrombocytopenia after FMR.
The CR rate upon completion of the entire treatment
regimen (FMR + 90Y-IT) was 89% (consisting of 49 out of 55
patients; 2 patients still maintained their PR status).
The addition of 90Y-IT improved the overall best response
(from PR to CR) in 11 of 13 patients who initially achieved PR
with FMR only: all of them obtained a cumulative CR (PET
negative). At a median follow-up time of 24 months (range 14–
38 months), 6 of 55 patients experienced progression. More
precisely, the consolidation therapy with 90Y-IT has
substantially improved the CR rate: among the 38 patients who
had a CR after induction, only 3 (8%) have shown a disease
relapse so far, at a median follow-up of 28 months (range 17–41
months). In force of these data, the estimated 3-year PFS is of
81% (95% confidence interval 54–93) and the 3-year OS rate is
of 100% (Figure 2).
In terms of molecular monitoring of MRD, 9 patients (26%)
out of the 35 tested for Bcl-2 expression showed Bcl2-IgH
negativity after the fourth cycle of FMR regimen; on the
contrary, 26 patients demonstrated a Bcl2-IgH positivity, 22 at
the major breakpoint region site and 4 at both major breakpoint
region and minor cluster region. These 26 cases were then
monitored for MRD during the follow-up: 21 patients achieved
molecular complete remission, 18 within 6 months after 90Y-IT,
and 3 after 12 months. Molecular relapse occurred in two
patients at a median follow-up of 20 months (range 12–36
months), without a clinically documented disease relapse.
Regarding the safety profile of the complete regimen, no
treatment-related deaths have occurred. The FMR regimen was
well tolerated by most of the patients, and reversible
hematologic toxic effects were the most common adverse
events. No grade 3–4 anemia was noted, whereas grade 3–4
neutropenia was observed in 19 patients, and grade 3–4
thrombocytopenia in 2 patients. Only one patient developed
febrile neutropenia. No 90Y-IT infusion-related reactions were
reported. Adverse events after radioimmunotherapy were
primarily hematologic and transient, and no patient has
discontinued treatment because of an adverse event. The
severity of the hematologic toxicity (expressed as the
lowest—nadir—concentration of granulocytes, platelets, and
hemoglobin) and its duration are reported in Table 2. Grade 3–
4 thrombocytopenia, neutropenia, and anemia occurred in the
55%, 42%, and 15% of patients, respectively. Twelve (22%)
patients received G-CSF, and transfusions of red blood cells,
platelets, or both were given to 18 (33%) patients. Four (7%)
patients experienced febrile neutropenia, but only one required
hospitalization.
No extra-hematologic adverse events have been reported; no
patients have shown a thyroid-stimulating hormone elevation,
nor any secondary malignancies have occurred.
discussion
This study has established the feasibility, tolerability, and
efficacy of a sequential treatment with four cycles of FMR
followed by 90Y-IT as a front-line therapy for untreated patients
with intermediate/high-risk follicular NHL. These data
represent the first evidence of a real role of 90Y-IT after
a fludarabine-containing regimen plus rituximab in the
treatment of high-risk follicular NHL, thus corroborating the
power of a sequential treatment, with the potential benefit of
reducing from 6 to 4 induction cycles because it is possible to
achieve the same therapeutic results [13] with the possibility, at
Table 1. Patients’ characteristics (n = 55)
Median age (range) (years) 56 (26–84)
Sex Male 25
Female 30
Bulky disease (‡10 cm) Yes 11
No 44
Extranodal involvement Yes 8
No 47
Stage (Ann Arbor) III 20
IV 35
Hemoglobin concentration (g/l) <120 22
‡120 33
Number of nodal areas >4 20
£4 35
Increased LDH concentration Yes 26
No 29
B-symptoms Yes 18
No 37
Bone marrow involvement Yes 30
No 25
FLIPI (score) Intermediate risk (2) 36
High risk (‡3) 19
B-symptoms: fever, weight loss, night sweats, pruritus sine materia.
LDH, lactate dehydrogenase; FLIPI, Follicular Lymphoma International
Prognostic Index.
Figure 1. Trial profile.
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the same time, of reducing the cumulative toxicity of the two
additional cycles of conventional chemotherapy.
Clinical evaluation of immunotherapy based on anti-CD20
monoclonal antibodies has markedly affected the treatment
approach for indolent follicular NHL [4–6, 24, 25]; at the same
time, the fluorinated nucleotide analogue fludarabine has
demonstrated activity in indolent NHL both as single agent and
in combination [26–28]. In parallel, radioimmunotherapy has
represented an innovative approach: particularly, 90Y-IT has
demonstrated to be one of the most active agents in the
treatment of lymphoma, with a manageable toxicity mainly
consisting of transient myelosuppression and antibody-
associated infusion reactions. Clinical trials with this agent have
shown significant activity in pretreated indolent NHL [8–11],
including chemotherapy or rituximab-resistant disease. On the
basis of these data, further investigations have monitored the
role of radioimmunotherapy as a consolidation treatment after
chemotherapy induction in follicular NHL patients: benefits in
this sense have been shown in a recent phase III trial [15], but
also in several phase II trials [13, 16–18], the results of which
are summarized in Table 3. Differently from our previous study
[13], this trial puts the accent on the use of rituximab in
combination with chemotherapy in a short, four-cycle
induction phase. In this sense, it differs from other trials [16–
18] as follows: i) only intermediate/high-risk patients were
included and ii) molecular response was evaluated.
By the end of the sequential combined treatment, 89% of
patients had achieved a CR, but more importantly, 11 patients
among the 13 in PR after FMR could achieve a CR after treatment
with 90Y-IT, with a molecular negativity in 21 out of 26 assessable
patients. 90Y-IT is therefore an important inducer of molecular
remission after conventional chemoimmunotherapy and it can
improve the quality of the clinical response by converting PR to
CR [24, 29], with generally mild and transient toxic effects.
Regarding the hematologic toxicity, there were no differences in
terms of grade 3–4 neutropenia and thrombocytopenia induced
by Zevalin after a fludarabine-containing regimen in comparison
with those observed after CHOP regimen and Zevalin [16].
If we compare the present results with our previous findings
of phase II ‘‘FLUMIZ’’ study [13], we note that the conversion
rate from PR to CR rate (86% in ‘‘FLUMIZ’’ versus 85% in this
study, P = 0.98) and the molecular response (78% versus 81%,
P = 0.93) are the same. The CR rate and the ORR presently
observed after induction were comparable to ‘‘FLUMIZ’’ ones:
69% versus 71% (P = 0.94) and 96% versus 98% (P = 0.94).
Similarly, the 3-year PFS was not significantly different (77%
versus 81%, P = 0.81). Although there is a theoretical concern
that rituximab may block potential binding sites for
radiolabeled monoclonal antibodies, this study has shown the
same percentage of conversion rate from PR to CR after 90Y-IT.
These data confirm the pivotal role played by
radioimmunotherapy as consolidation treatment after an
induction phase: CR and PFS rates turned out to be superior if
compared with those obtained by conventional
chemoimmunotherapy front-line treatments, such as R-CVP
Table 2. Hematologic toxic effects after 90Y-ibritumomab tiuxetan
Nadir,
median
(range)
Median
duration
of grade 3–4
cytopenia*
(range), days
Absolute neutrophil count 710, 106 cells/l
(80–2230)
31 (6–92)
Platelets 21, 109 cells/l
(5–95)
29 (11–72)
Hemoglobin 98, g/l)
(75–139)
30 (18–91)
*Defined as: platelets <50109/l; hemoglobin <80 g/l; neutrophils <1000106/l.
Table 3. First-line consolidation treatment with 90Y-ibritumomab tiuxetan
Reference Treatment Pts N CR after induction (%) CR after 90Y-IT (%) PFS
Jacobs et al. [16] 3xR-CHOP/90Y-IT/4xR 60 46 89 78% at 2 years
Hainsworth et al. [17] 4xR/3xR-CHOP or
R-CVP/90Y-IT
41 30 72 64% at 5 years
Zinzani et al. [13] 6xFM/90Y-IT 61 70 96 76% at 3 years
Morschhauser et al. [15] Various/90Y-IT 208 51 87 Median 36.5 months
McLaughlin et al. [18] 4xR-FND/90Y-IT/
R-maintenance
35 69 89 74% at 3 years
This study 4xFNR/90Y-IT 55 69 89 80% at 3 years
R, rituximab; 90Y-IT, 90Y-ibritumomab tiuxetan.
Figure 2. Kaplan–Meier curves for overall survival and progression-free
survival with FMR regimen (four cycles) followed by 90Y-ibritumomab
tiuxetan in untreated patients with high-risk follicular NHL.
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[4] and R-CHOP [5]. Chemoimmunotherapy with following-
on radioimmunotherapy has also demonstrated a higher
efficacy, in terms of final CR and PFS rate, in comparison with
radioimmunotherapy only (131I-tositumomab) as initial
treatment [30].
This study, along with other published data [15–18], suggests
that radioimmunotherapy consolidation could be an important
treatment approach for patients with follicular NHL.
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